

Electronically Filed February 6, 2007

REQUEST FOR CORRECTED FILING RECEIPT	Attorney Docket	AREN-005CON (5.US10.CON)
Address to:	Applicant	BEHAN, DOMINIC P. et al.
Mail Stop OIPE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Serial Number	10/668,035
	Filing Date	September 22, 2003
	Group Art Unit	1646
	Examiner Name	BASI, NIRMAL SINGH
	Title:	<i>"ENDOGENOUS CONSTITUTIVELY ACTIVATED G PROTEIN-COUPLED ORPHAN RECEPTORS"</i>

Sir:


A filing receipt for the above-identified patent application has been issued by the U.S. Patent and Trademark Office (copy attached).

Please correct the Atty Docket No. to read: AREN-005CON (5.US10.CON) as indicated on the marked-up filing receipt attached herewith.

If for any reason a fee is found to be necessary, the Commissioner is authorized to charge such fee to Deposit Account No. 50-0815.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP


Carol L. Francis, Ph.D.
Registration No. 36,513

Date: February 6, 2007

By:

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

MPS/aw

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/668,035	09/22/2003	1614	375	AREN-OUTCON AREN-OUTCON(S.US10.CON)	34	19	2

~~AREN-OUTCON~~
AREN-OUTCON(S.US10.CON)

CONFIRMATION NO. 2177

35133
COZEN O'CONNOR, P.C.
1900 MARKET STREET
PHILADELPHIA, PA 19103-3508

UPDATED FILING RECEIPT



OC000000012372142

Date Mailed: 04/16/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Dominic P. Behan, San Diego, CA;
Derek T. Chalmers, Cardiff, CA;
Chen W. Liaw, San Diego, CA;
I-Lin Lin, San Diego, CA;
Kevin P. Lowitz, Sunnyvale, CA;
Ruoping Chen, San Diego, CA;

APR 20 2004

N/K

Assignment For Published Patent Application

Arena Pharmaceuticals, Inc., San Diego, CA;

Domestic Priority data as claimed by applicant

This application is a CON of 09/364,425 07/30/1999 PAT 6,653,086
which is a CIP of 09/060,188 04/14/1998
and claims benefit of 60/094,879 07/31/1998
and claims benefit of 60/106,300 10/30/1998
and claims benefit of 60/110,906 12/04/1998
and claims benefit of 60/121,851 02/26/1999

RECEIVED
COZEN IP DEPT.

APR 20 2004

DUE DATE N/A
MAX DATE 11/17
DOCKETED BY JNC

Foreign Applications

If Required, Foreign Filing License Granted: 01/21/2004

Projected Publication Date: 07/29/2004

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Endogenous, constitutively activated G protein-coupled orphan receptors

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).